Literature DB >> 23466655

Preoperative statin therapy in cardiac surgery is more effective in patients who display preoperative activation of the inflammatory system.

José Martínez-Comendador1, José Rubio Alvarez, Juan Sierra, Elvis Teijeira, Belén Adrio.   

Abstract

We sought to determine whether preoperative statin treatment is more effective in reducing, after cardiac surgery with cardiopulmonary bypass, systemic inflammatory response and myocardial damage markers in patients who have elevated preoperative interleukin-6 levels than in patients who have normal preoperative interleukin-6 levels. The study involved a prospective cohort of 164 patients who underwent coronary and valvular surgery with cardiopulmonary bypass. There were 2 study groups: group A (n = 60), patients with elevated preoperative interleukin-6 levels; and group B (n = 104), patients with normal preoperative interleukin-6 levels. Each group was subdivided according to whether patients were (group 1) or were not (group 2) treated preoperatively with statins. Accordingly, the subdivided study groups were A1 (n = 40), A2 (n = 20), B1 (n = 56), and B2 (n = 48). The plasma levels of proinflammatory interleukin-6 were measured 1, 6, 24, and >72 hours after surgery. The baseline, operative, and postoperative morbidity and mortality characteristics were similar in all groups. Group A1 had significantly lower levels of interleukin-6 and troponin I than did group A2 at all postoperative time points. Group B1 had significantly lower levels of interleukin-6 than did group B2 postoperatively. There were no significant differences in troponin I levels between groups B1 and B2. We conclude that, in patients with preoperative activation of the inflammatory system, preoperative treatment with statins is associated with lower postoperative interleukin-6 and troponin I levels after cardiac surgery with cardiopulmonary bypass.

Entities:  

Keywords:  Anticholesteremic agents/therapeutic use; biological markers; coronary artery bypass/adverse effects; inflammation mediators; interleukin-6/blood; postoperative complications/blood; statin treatment; systemic inflammatory response syndrome/prevention & control; troponin/blood

Mesh:

Substances:

Year:  2013        PMID: 23466655      PMCID: PMC3568290     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  28 in total

1.  Statin therapy and the acute inflammatory response after coronary artery bypass grafting.

Authors:  D J Brull; J Sanders; A Rumley; G D Lowe; S E Humphries; H E Montgomery
Journal:  Am J Cardiol       Date:  2001-08-15       Impact factor: 2.778

2.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.

Authors:  G G Schwartz; A G Olsson; M D Ezekowitz; P Ganz; M F Oliver; D Waters; A Zeiher; B R Chaitman; S Leslie; T Stern
Journal:  JAMA       Date:  2001-04-04       Impact factor: 56.272

3.  Perioperative statin therapy reduces mortality in normolipidemic patients undergoing cardiac surgery.

Authors:  Muthiah Vaduganathan; Neil J Stone; Richard Lee; Edwin C McGee; S Chris Malaisrie; Robert A Silverberg; Preeti Kansal; Patrick M McCarthy
Journal:  J Thorac Cardiovasc Surg       Date:  2010-09-18       Impact factor: 5.209

Review 4.  Statins and coronary artery bypass graft surgery: preoperative and postoperative efficacy and safety.

Authors:  Alexander Kulik; Marc Ruel
Journal:  Expert Opin Drug Saf       Date:  2009-09       Impact factor: 4.250

5.  Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?

Authors:  R John Simes; Ian C Marschner; David Hunt; David Colquhoun; David Sullivan; Ralph A H Stewart; Wendy Hague; Anthony Keech; Peter Thompson; Harvey White; John Shaw; Andrew Tonkin
Journal:  Circulation       Date:  2002-03-12       Impact factor: 29.690

6.  Inflammatory/oxidative stress during the first week after different types of cardiac surgery.

Authors:  Inga Karu; Günter Taal; Kersti Zilmer; Chris Pruunsild; Joel Starkopf; Mihkel Zilmer
Journal:  Scand Cardiovasc J       Date:  2010-04       Impact factor: 1.589

Review 7.  Interleukin-6 and cardiovascular diseases.

Authors:  Tsugiyasu Kanda; Takashi Takahashi
Journal:  Jpn Heart J       Date:  2004-03

8.  Urine interleukin-6 is an early biomarker of acute kidney injury in children undergoing cardiac surgery.

Authors:  Paula Dennen; Christopher Altmann; Jonathan Kaufman; Christina L Klein; Ana Andres-Hernando; Nilesh H Ahuja; Charles L Edelstein; Melissa A Cadnapaphornchai; Angela Keniston; Sarah Faubel
Journal:  Crit Care       Date:  2010-10-13       Impact factor: 9.097

9.  Serum interleukin-6 and interleukin-8 are early biomarkers of acute kidney injury and predict prolonged mechanical ventilation in children undergoing cardiac surgery: a case-control study.

Authors:  Kathleen D Liu; Christopher Altmann; Gerard Smits; Catherine D Krawczeski; Charles L Edelstein; Prasad Devarajan; Sarah Faubel
Journal:  Crit Care       Date:  2009-07-01       Impact factor: 9.097

10.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.